MAPT and Alzheimer disease: While a positive Aβ PET is not sufficient to confirm AD pathology as the primary cause and it may be necessary to combine this finding with other biomarkers, primarily tau PET [192,193], when negative, Aβ PET allows ruling out the presence of an underlying AD pathology [182].